학술논문

Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial †

Document Type

article

Author

Clement, PM; Gauler, T; Machiels, JP; Haddad, RI; Fayette, J; Licitra, LF; Tahara, M; Cohen, EEW; Cupissol, D; Grau, JJ; Guigay, J; Caponigro, F; de Castro, G; de Souza Viana, L; Keilholz, U; del Campo, JM; Cong, XJ; Ehrnrooth, E; Vermorken, JB

Source

Annals of Oncology. 27(8)

Subject

Biomedical and Clinical Sciences
Clinical Sciences
Oncology and Carcinogenesis
Clinical Research
Dental/Oral and Craniofacial Disease
Cancer
Clinical Trials and Supportive Activities
Rare Diseases
Evaluation of treatments and therapeutic interventions
6.1 Pharmaceuticals
Good Health and Well Being
Afatinib
Aged
Aged
80 and over
Antineoplastic Combined Chemotherapy Protocols
Carcinoma
Squamous Cell
Disease-Free Survival
Female
Head and Neck Neoplasms
Humans
Male
Methotrexate
Neoplasm Metastasis
Neoplasm Recurrence
Local
Platinum
Quinazolines
Squamous Cell Carcinoma of Head and Neck
Treatment Outcome
LUX-H&N 1 investigators
HNSCC
afatinib
methotrexate
older
phase III
second-line
Oncology & Carcinogenesis
Clinical sciences
Oncology and carcinogenesis

Language

Abstract

BackgroundIn the phase III LUX-Head & Neck 1 (LHN1) trial, afatinib significantly improved progression-free survival (PFS) versus methotrexate in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients progressing on/after platinum-based therapy. This report evaluates afatinib efficacy and safety in prespecified subgroups of patients aged ≥65 and

Online Access

Open Access (eScholarship) Find it@PNU

이메일

부산대학교 도서관

Online Access

메일 발송